Dr Baird outlines the background of the POSEIDON trial of the EurocanPlatform project, an investigator-led trial in metastatic breast cancer that is hormone receptor positive and HER2-negative. The trial is examining a combination of Tamoxifen with PI-3 kinase inhibitor.
EurocanPlatform is an EC funded project bringing together 28 European cancer Institutions and organisations to work together in a unique collaboration. The centres are sharing infrastructures and collaborating on projects to help advance cancer research and treatment.
He explains how the EurocanPlatform project has been instrumental in bringing the trial to life, what challenges have been faced and what they expect for the remainder of the trial in the future.
Watch this video on the highlights of the project.